TORONTO, July 24, 2020 (GLOBE NEWSWIRE) — Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or “Blueberries“), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce call-in numbers and webcast link for the Annual General and Special Meeting of the shareholders of Blueberries Medical Corp. (the “AGM”).
The AGM will be held on Friday, July 31, 2020 at 1:00 pm Eastern Time at 82 Richmond Street East, Toronto, Ontario, Canada M5C 1P1.In response to the ongoing global COVID-19 pandemic, the board of directors of Blueberries is advising shareholders not to attend the AGM in-person. After considering recent Provincial and Federal guidance regarding public gatherings and to proactively protect the health and well-being of Blueberries’ shareholders, employees, and service partners who participate in the AGM, the AGM will also be hosted in a virtual setting via webcast and teleconference.In order to streamline the meeting process, the Company strongly encourages shareholders to vote in advance of the meeting using the Form of Proxy or Voting Instruction Form mailed to them with the meeting materials. Comprehensive information with respect to how registered and beneficial shareholders may vote in advance of the meeting is available in Blueberries’ Management Information Circular, also filed on SEDAR.The deadline to vote your proxy in advance of the meeting is 1:00 pm, Eastern Time on Wednesday, July 29, 2020.The webcast and teleconference will allow shareholders to listen to the proceedings and ask questions verbally through the teleconference. Details for shareholders interested in calling-in to the meeting are below. Participants should login and/or dial in approximately 10 minutes prior to the start time.Webcast: Join Zoom Meeting
https://us02web.zoom.us/j/88129348804?pwd=M05BelRzUU9WM0ZvWWxYTGIvTVIzQT09Following the formal proceedings of the AGM, management will provide a business update and presentation. All interested parties are invited to attend the AGM and participate in the management update.
About Blueberries Medical Corp.
Blueberries is a Latin American licensed producer of naturally grown premium quality cannabis with its primary operations ideally located in the Bogotá Savannah of central Colombia. The Company is led by a specialized team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology and marketing, Blueberries is fully licensed for the cultivation, production, domestic distribution, and international export of CBD and THC-based medical cannabis in Colombia. Blueberries’ combination of leading scientific expertise, agricultural advantages and distribution arrangements has positioned the Company to become a leading international supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts and related products.Additional information about the Company is available at www.blueberriesmed.com.For more information, please contact:
Camilo Villalba, Chief Executive Officer
Tel: +57 (313) 483 0131Ian Atacan, Chief Financial Officer
Tel: +1 (416) 562 3220Cautionary Note Regarding Forward-Looking Information
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking statements relate, among other things, to: closing of the proposed transactions and achieving milestones in 2019 as contemplated, or at all, ability to expand distribution networks, ability to expand and upgrade the Company’s cultivation facilities in Colombia, internal expectations, expectations regarding the ability of the Company to access new Latin American and international markets, the ability to attract and retain new customers, and future expansion plans including development of the cultivation, production, industrialization and marketing of cannabis for commercial and scientific purposes.These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Colombian and international medical cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in Colombia, Argentina and elsewhere; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.Additional information regarding the Company, and other risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s Listing Statement dated January 31, 2019 filed on its issuer profile on SEDAR at www.sedar.com.No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
Sixth Wave Continues Phase 2 Rapid COVID Test Development and Receives Funding from Nova Scotia COVID-19 Response Council
Halifax, Nova Scotia–(Newsfile Corp. – October 27, 2020) – Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: ATURF) (FSE: AHUH) (“Sixth Wave”, “SIXW” or the “Company”) is pleased to announce that it has received a $250,000 contribution from the Nova Scotia COVID-19 Response Council (“NSCRC”) for the development of its proposed AMIPs™ technology for the rapid detection of viruses such as SARS-CoV-2 (“SARS-CoV-2” or the “Virus“). AMIPs™ is based on Sixth Wave’s patented and patent-pending molecularly imprinted polymer systems.
Under the terms of the Agreement, dated October 22, 2020, Sixth Wave will continue to develop an Accelerated Molecularly Imprinted Polymer (the “AMIPs™“) specifically for the purpose of quickly and selectively binding to the Virus. The proposed technology also contemplates the rapid delivery of a visual and/or electronic response upon the detection and verification of the Virus. The Company’s intention is to incorporate the AMIPs™ technology into a several rapid-detection products, including rapid virus test kits, SmartMask™, as well as air and water monitoring systems. The ability to have the AMIPs™ detection and reporting directly integrated into devices such as Personal Protective Equipment (PPE’s) will seamlessly provide the detection and the ability to automatically disseminate results for use in outbreak tracking and contact tracing (as may be implemented by appropriate Government agencies). The development of the air monitoring technology is the subject of the Company’s previously approved and announced (June 15, 2020) collaboration with York University and Centre Technologique des Residus Industriels which has received support from the Natural Sciences and Engineering Research Council of Canada (“NSERC”).
This Project represents the first outside funding in the development of the Company’s proposed AMIPs™ virus detection technology, and expands the SIXW footprint in Nova Scotia. As previously announced (May 15, 2020), SIXW has already engaged Neocon International Inc., a premier manufacturing company in Dartmouth to commercialize the SmartMask™ product. Moreover, SIXW has executed a Memorandum of Understanding with Dalhousie University to explore near term opportunities to establishing a research and development presence in the Province.
“Our sincere appreciation to the Province of Nova Scotia for its participation in this project,” said Dr. Jon Gluckman, CEO of Sixth Wave. “Sixth Wave has a substantial history of delivering similarly complex MIP based solutions within limited timelines, as evidenced by our explosives detection wipes and bacterial pathogen diagnostic tools. We welcome this opportunity to once again prove the utility of molecular imprinting as a detection and diagnostic tool, especially in circumstances of such importance to public health and security.”
“MIP technology is well documented in the scientific literature as being a comparatively fast and reliable diagnostic tool,” said Garrett Kraft Ph.D., head of the Sixth Wave project. “MIP-based analytical technologies are also known for their flexibility, durability and accuracy. Polymer substrates demonstrate resilience under adverse conditions, and do not require climate-controlled storage as many antibody based tests do. They can therefore be readily applied to a host of materials, fabrics and other test media. These attributes along with low cost and production scalability have the potential to set AMIPs™ apart from traditional PCR and immunoassay tests.”
The company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 coronavirus) at this time. AMIPs tests produced for personal use or point of care use will be subject to regulatory approval.
The Project has a number of objectives, culminating in the development of a Molecularly Imprinted Polymer (“MIP“) formulation with measurable binding of inactivated SARS-CoV-2 in a buffer solution with limits of detection less than 15,000 virus particles / mL (comparable to several other commercially available diagnostic technologies) and a basic colorimetric response using protein labeling chemistry. Clinically relevant viral loads have been determined to be approximately 15,000 virus particles / mL. Although a MIP for the detection of SARS-CoV-2 has not previously been developed, other virus imprinted polymers have demonstrated detection limits as low as 105 virus particles / mL.
Overall, the Company’s objectives for the COVID-selective AMIPs™ include:
- Flexibility – The ability to analyze a significant variety of field samples such as specimens garnered from bodily fluids, breath, air, waste streams, and contact surfaces;
- Speed – The ability to detect and to communicate an electronic or visual signal almost immediately upon positive diagnosis;
- Ease Of Use – The ability to integrate with a variety of devices not requiring specialized training, and
- Low Cost – enabling widespread and frequent testing that will allow for safe return to daily activities and outbreak management.
The Company’s COVID-19 Project represents the first step in the development of a flexible platform which can be adapted to detect virtually any virus. For more information on the proposed AMIPs™ technology and associated fundamental and device-related patent applications, see: www.amips.com.The overall budget for this Project totals $770,000, of which $250,000 will be funded through the contribution by the NSCRC.
The Company’s molecularly imprinted polymer technology is also being commercialized in the mining and cannabis sectors.
About Sixth Wave
Sixth Wave is a nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs). The Company is in the process of commercial roll out of its Affinity™ cannabinoid purification system, as well as, IXOS®, a line of extraction polymers for the gold mining industry. The Company is in the development stages of a rapid diagnostic test for viruses under the Accelerated MIPs (AMIPS™) label.
Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for detection and separation of viruses, biogenic amines and other pathogens, for which the Company has products at various stages of development.
For more information about Sixth Wave, please visit our web site at: www.sixthwave.com
ON BEHALF OF THE BOARD OF DIRECTORS
Jonathan Gluckman, Ph.D., President & CEO
For information, please contact the Company:
Phone: (801) 582-0559
This press release includes certain statements that may be deemed “forward-looking statements” including statements regarding the planned use of proceeds and performance of the AMIPs™ technologies. All statements in this release, other than statements of historical facts, that address future events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual events or developments may differ materially from those in forward-looking statements. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause the Company’s actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. In particular, successful development and commercialization of the AMIPs™ technology are subject the risk that the AMIPs™ technology may not prove to be successful in detecting virus targets effectively or at all, uncertainty of medical product development, uncertainty of timing or availability of required regulatory approvals, lack of track record of developing products for medical applications and the need for additional capital to carry out product development activities. The value of any products ultimately developed could be negatively impacted if the patent is not granted. The Company has not yet completed development of a prototype for the product that is subject of its patent application and has not yet applied for regulatory approval for the use of this product from any regulatory agency.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66918
Curtis Mathes to Present a Live Webinar for Cannabis Science & Technology
The Curtis Mathes Corporation (OTC: TLED) will be presenting a live webinar on November 3rd in collaboration with the peer-reviewed technical journal, Cannabis Science & Technology. The presentation, entitled “Environmental and Genetic Factors that affect the quality of Cannabis and Hemp”, will be delivered by Dr. Zacariah Hildenbrand along with a live Q&A session.
“We are thrilled to share this educational webcast with our audience as well as the knowledge and thought-leadership from one of our esteemed editorial advisory board members, Dr. Zacariah Hildenbrand,” said Meg L’Heureux, Editor-in-Chief of Cannabis Science & Technology.
“It is always a tremendous honor to disseminate new information regarding the interplay between plants and the environment,” remarked Zacariah Hildenbrand, Curtis Mathes Director and Chief Scientific Officer, “This webinar hosted by Cannabis Science & Technology is an excellent opportunity for us to discuss our latest lighting technologies and ongoing research efforts.”
“Science and research are entrenched in our DNA at Curtis Mathes,” said Robert Manes, President & COO of Curtis Mathes, “Webinars like this allow us to connect with potential collaborators while educating prospective clients on the science of horticultural lighting.”
Santa Cruz Dispensary, KindPeoples Partnering with Cannabis Brands to Offer Fire Relief Program
Santa Cruz, California–(Newsfile Corp. – October 27, 2020) – California’s wildfire season has brought unprecedented devastation and loss to so many this year. In Santa Cruz, the CZU Lightning Complex Fire destroyed more than 900 homes and at its most ferocious, required the evacuation of tens of thousands of people.
At KindPeoples, the largest cannabis retailer in Santa Cruz County, we have been heartened by the tremendous acts of bravery shown by firefighters and first responders and shared in the heartache of the individuals and families impacted by the wildfires.
“We are grateful to the firefighters who worked tirelessly to contain the wildfires in Santa Cruz and are continuing the dangerous work at hotspots throughout our state,” said Khalil Moutawakkil, KindPeoples Co-CEO. “After seven months of living through a pandemic and then confronting the fury of wildfires, we knew we had to do our part in supporting local evacuees and the organizations that are helping the firefighters and localities impacted by fires across California.”
During the month of September, in addition to a company donation that went to local charities supporting Santa Cruz County residents impacted by the CZU Lightning Complex Fire, KindPeoples offered a 25% off store-wide discount to local evacuees. More than 700 individuals redeemed the discount, amounting to $28,730 in customer savings.
Starting Thursday, October 1, when shoppers purchase select items from the following brands, a portion of the sale will be donated to organizations that support restoration and wildfire education, firefighters and communities impacted by the wildfires locally and throughout California.
Participating brands include: Heavy Hitters, Dollar Dose, Kanha Treats, Chemistry, Big Pete’s Treats, Buddies, Sensi Chews, Yummi Karma, Papa & Barkley, and High Gorgeous.
Products that are a part of the program are identified by a “Fire Relief” sticker.
“We are so honored to be a part of KindPeoples Fire Relief Program. Bringing cannabis brands together for a collective goal is what it’s all about, and we are excited to see what an impact we can make together,” said Kirstie Price, regional manager for Heavy Hitters. “The Santa Cruz community has given us so much over the years, this initiative is one of a handful of small steps we are taking to offer a little something back. We are thankful that our local team members have not been directly impacted by the wildfires.”
KindPeoples is locally-owned and operated, independently-funded, with two locations in Santa Cruz: 533 Ocean Street, Santa Cruz, 95060 and 3600 Soquel Avenue, Santa Cruz, 95062. Founded in 2014, KindPeoples was the first state-licensed cultivator, manufacturer, distributor, retailer and micro-business in Santa Cruz.
Since its opening, KindPeoples has focused on being the top cannabis retailer in the region and has been voted each year the “best cannabis dispensary” in Santa Cruz County by the local community in the Good Times readers’ poll, “Best Of”, Santa Cruz County’s largest circulating newspaper. KindPeoples stocks professionally curated, top-shelf, in-demand cannabis and CBD products.
Roseann Cattani – PR Specialist,
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66853
Cannabis4 weeks ago
MustGrow Commences Banana ‘Panama Disease’ Testing in Colombia
Cannabis3 weeks ago
Bud & Tender® raise testing and quality standards for best CBD oil in the UK
Cannabis3 weeks ago
The World’s Greatest Weight Loss Secret May be Psilocybin
Cannabis4 weeks ago
MediPharm Labs Secures 100% Ownership of its Australia Subsidiary, Poised for New Wave of Global Medicinal Cannabis Growth
Cannabis2 weeks ago
Aither Ingredients Announces Joint Venture With Thar Process Intended to Disrupt the Canadian Cannabis-based Ingredient Market
Cannabis4 weeks ago
WeedMD Reports Second Quarter 2020 Financial Results and Closes $30 Million Credit Facility with LiUNA Pension Fund
Cannabis4 weeks ago
PAOG Engages Saul Kaye, Founder of iCAN: Israel-Cannabis and CannaTech to Prepare RespRx for IND
Cannabis4 weeks ago
Christina Lake Announces Commencement of Trading on the CSE